Riskpilot← Back to searchSign inGet full accessVETTRE APOTEK AS
ASActiveOrg 919898372Konglungveien 206, 1392 VettreRetail sale of pharmaceutical products · NACE 4773Est. 20172 employees
Revenue 2024
NOK 16,9M
+33% vs 2023
EBITDA margin
6.7%
+168% vs 2023
Equity ratio
13.2%
Financial strength
Net profit 2024
NOK 996K
+300% vs 2023
| Revenue | NOK 16,9M | +33% |
| EBITDA | NOK 1,1M | +168% |
| Net profit | NOK 996K | +300% |
| Total assets | NOK 2,8M | -27% |
| Equity | NOK 365K | +158% |
| Employees | 2 | — |
Legal name
VETTRE APOTEK AS
Org number
919898372
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
13. november 2017
Share capital
NOK 2 250 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Apotekdrift, samt alt som hører naturlig til dette.
Address
Konglungveien 206, 1392 Vettre
Phone
+4767206690
Email
post@vettreapotek.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 9 357 | 11 590 | 10 834 | 12 746 | 16 916 |
| Staff expenses | −2 141 | −2 103 | −1 919 | −2 028 | −1 980 |
| EBITDA | −91 | 65 | 97 | 423 | 1 132 |
| Depreciation & amort. | −124 | −124 | −124 | −87 | −75 |
| EBIT | −215 | −59 | −27 | 336 | 1 057 |
| Net financials | −66 | −62 | −67 | −87 | −61 |
| Profit before tax | −281 | −121 | −94 | 249 | 996 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −281 | −121 | −94 | 249 | 996 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 744 | 2 425 | 1 866 | 3 808 | 2 776 |
| Equity | −664 | −785 | −879 | −630 | 365 |
| Long-term debt | 1 500 | 1 500 | 1 500 | 1 500 | 300 |
| Short-term debt | 1 908 | 1 710 | 1 245 | 2 938 | 2 111 |
| Total debt | 3 408 | 3 210 | 2 745 | 4 438 | 2 411 |
EBITDA margin
6.7%
This company
15.8%
Market median
-58% vs market
20202024
Equity ratio
13.2%
This company
38.2%
Market median
-65% vs market
20202024
Return on equity
272.5%
This company
18.4%
Market median
+1381% vs market
20202024
Net profit margin
5.9%
This company
8.1%
Market median
-27% vs market
20202024
Asset turnover
6.09×
This company
1.12×
Market median
+444% vs market
20202024
Debt / equity
6.60×
This company
0.62×
Market median
-965% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
IB Chief Executive Officer | Chief Executive Officer | 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2019 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 33.33% | 33.33% | 2022 | |
| Individual | 22.22% | 22.22% | 2022 | |
| Individual | 22.22% | 22.22% | 2022 | |
| Company | 11.11% | 11.11% | 2022 | |
| Individual | 11.11% | 11.11% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of VETTRE APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Idar Bakke | Chief Executive Officer | 0 companies |
| Ragnar Salmen | Board of Directors | 0 companies |